Salpingotus crassicauda
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA1119565 | ENA |
REPOSITORIES: ENA
Dataset's files
| Action | DRS | |||
|---|---|---|---|---|
| Other | ||||
| SRR29313569_1.fastq.gz | Fastqsanger.gz | |||
| SRR29313569_2.fastq.gz | Fastqsanger.gz | |||
| SRR29313570_1.fastq.gz | Fastqsanger.gz | |||
| SRR29313570_2.fastq.gz | Fastqsanger.gz |
Items per page: 5 1 - 5 of 16 |
Similar Datasets
Project description:Androctonus crassicauda Raw sequence reads
| PRJNA1040746 | ENA
Project description:In the present study, we report for the first time a proteomic profile of Buthotus saulcyi, Odontobuthus doriae and Androctonus crassicauda scorpion venom with the aim of looking ahead and determining the structural and functional characteristics of these compounds for use as medical tools. Molecular weight determination of isolated proteins was performed in order to better describe the B. saulcyi, O. doriae and A. crassicauda raw toxin proteins by both polyacrylamide electrophoresis and two-dimensional electrophoresis. 2D-PAGE data from the B. saulcyi, O. doriae and A. crassicauda raw toxin showed a molecular weight between 3.6 and 205 kDa (for B. saulcyi), 6.6 to 205 kDa (for O. doriae) and 6.6-109 kDa (for A. crassicauda). Then 14, 14 and 21 fractions of crude toxins were isolated using HPLC and their protein content was estimated for B. saulcyi, O. doriae and A. crassicauda, respectively. SDS-PAGE analysis of selected fractions of crude toxin showed 9 protein bands with a molecular weight between 13 and 217 kDa for B. saulcyi, 10 protein bands with a molecular weight between 3.8 to182 kDa for O. doriae and 5 protein bands with a molecular weight between 5.99 and 41.65 kDa for A. crassicauda. In case of B. saulcyi, the fraction 7 (F7) showed more cytotoxicity than other isolated fractions. Subsequently, the amino acid sequencing of fraction 7 led us to two protein bands designated as p3 and p4 peptide. For O. doriae, the peptide fraction of F17, obtained from the crude venoms of O. doriae scorpion, was found to be more cytotoxic than the crude venoms and other isolated fractions. Furthermore, F5 demonstrated significant anti-proliferative and apoptotic activity. Therefore, we performed PAGE on fraction F5 and found 5 protein bands. The two protein bands, each from fraction F5 that marked as P1 and P2 were selected for amino acid sequencing. The three peptide fractions F17, obtained from the crude venoms of A. crassicauda scorpion, was found to be more cytotoxic than the crude venoms and other isolated fractions. Furthermore, F17 demonstrated significant anti-proliferative and apoptotic activity. This makes this fraction better candidate for searching the peptide that might be used for selective killing of cancerous cells. Therefore, we performed PAGE on fractionsF17, and found 2 protein bands. One protein band from fraction F17 that marked as P5 was selected for amino acid sequencing. Finally, these protein bands were removed and molecular mass and amino acid sequence analysis was performed using Laser Desorption/Ionization Time-of-Flight Mass Spectrometry (MALDI-TOF MS). In-silico studies of P1, P2, P3, P4 and P5 for protein sequence alignment showed the most similarity with Hemoglobin beta-2 chain protein, Chaperonin HSP60, Chrysophsin2, pheromone-bound protein 2 and Trypsin- like serine proteinase, respectively
2023-05-10 | PXD036231 | Pride
Project description:Systematic and computational identification of Androctonus Crassicauda long non-coding RNAs
| PRJNA687110 | ENA
Project description:Crassicauda magna isolate Ningbo Raw sequence reads
| PRJNA731245 | ENA
Project description:Androctonus crassicauda strain:Androctinus crassicoda Raw sequence reads
| PRJNA1040487 | ENA
Project description:Primary objectives: The primary objective is to investigate circulating tumor DNA (ctDNA) via deep sequencing for mutation detection and by whole genome sequencing for copy number analyses before start (baseline) with regorafenib and at defined time points during administration of regorafenib for treatment efficacy in colorectal cancer patients in terms of overall survival (OS).
Primary endpoints: circulating tumor DNA (ctDNA) via deep sequencing for mutation detection and by whole genome sequencing for copy number analyses before start (baseline) with regorafenib and at defined time points during administration of regorafenib for treatment efficacy in colorectal cancer patients in terms of overall survival (OS).
| 2533916 | ecrin-mdr-crc
Project description:The potential function of long non-coding RNAs in regulating neighbor protein-coding genes has attracted scientists' attention. Despite the important role of lncRNAs in biological processes, a limited number of studies focus on non-model animal lncRNAs. In this study, we used a stringent step-by-step filtering pipeline and machine learning-based tools to identify the specific Androctonus crassicauda lncRNAs and analyze the features of predicted scorpion lncRNAs. 13,401 lncRNAs were detected using pipeline in A. crassicauda transcriptome. The blast results indicated that the majority of these lncRNAs sequences (12,642) have no identifiable orthologs even in closely related species and those considered as novel lncRNAs. Compared to lncRNA prediction tools indicated that our pipeline is a helpful approach to distinguish protein-coding and non-coding transcripts from RNA sequencing data of species without reference genomes. Moreover, analyzing lncRNA characteristics in A. crassicauda uncovered that lower protein-coding potential, lower GC content, shorter transcript length, and less number of isoform per gene are outstanding features of A. crassicauda lncRNAs transcripts.
| S-EPMC7907363 | biostudies-literature
Project description:The study is intended to collect specimens to support the application of genome analysis technologies, including large-scale genome sequencing. This study will ultimately provide cancer researchers with specimens that they can use to develop comprehensive catalogs of genomic information on at least 50 types of human cancer. The study will create a resource available to the worldwide research community that could be used to identify and accelerate the development of new diagnostic and prognostic markers, new targets for pharmaceutical interventions, and new cancer prevention and treatment strategies. This study will be a competitive enrollment study conducted at multiple institutions.
| 2140168 | ecrin-mdr-crc